VIRTUAL INVESTOR BRIEFING 5 February 2021 – Perth, Australia:...

VIRTUAL INVESTOR BRIEFING
5 February 2021 – Perth, Australia: PharmAust Limited (ASXAA), a clinical-stage oncology company, is pleased to announce it is holding a Virtual Investor Briefing on Thursday 11 February 2021 from 1:30 pm AWST / 4:30 pm AEDST & 5:30 am UK time.
Executive Chairman, Dr Roger Aston will provide a brief update on the status of the development of the Company’s primary drug candidate, Monepantel (MPL) including discussion on the various initiatives including Phase IIb Canine Cancer Trial, Phase II Human Cancer Trial, COVID-19 Testing, Phase I/II Human Trial in Motor Neurone Disease, and other activities.
Epichem CEO, Colin La Galia will provide an update on wholly owned subsidiary Epichem Pty Ltd including the status on the exciting biofuels and fine chemicals proprietary project.
The Virtual Investor Briefing will be viewed live via Zoom over the internet and will provide investors the opportunity for Q&A.
Please register for this event using the following link:

https://us02web.zoom.us/webinar/register/WN_VE5aYnp_QcixznDXNjnqHQ

Shareholders are encouraged to submit questions in advance of the Virtual Investor Briefing by emailing
[email protected]
A recorded copy of the Virtual Investor Briefing will be made available on the PharmAust website following the event.
This announcement is authorised by the Board.
Enquiries:
Sam Wright PharmAust Limited Finance [email protected]
About PharmAust (PAA):
Daniel Rootes
JP Equity Partners
Corporate Advisor – Asia/[email protected]
PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated $3.5 million in revenue in FY 2020.
PAA’s lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com